App-Quantinova.ai

Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Munster AML Study Group.

C. Michel Zwaan - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Disseminated intravascular coagulation

N/A

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Nizar J. Bahlis - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Short Term Signalling Responses of the Most Primitive Subsets of Human Hematopoietic Cells Stimulated in Vitro Correlate with Their Subsequent Self-Renewal Behaviour.

Sean C. Bendall - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Filgrastim

Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells.

Boris Bartholdy - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Can Common Coagulation Assays Be Used to Estimate Dabigatran or Rivaroxaban Concentration? An Interlaboratory Comparison of 41 Hospitals in Quebec.

Chantal Nadeau - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Transfusion Managament in Cardiac Surgery in British Columbia: Review of 8352 Patients.

Kate M Chipperfield - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congenital heart disease

N/A

A Comparison of Automated Red Blood Cell Depletion/Exchange to Automated Red Cell Blood Exchange in Sickle Cell Patients.

David Barth - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sickle cell anemia

Caridian

Studies in C4b-Deficient Mice Provide Further Evidence That Complement Cascade Orchestrates the Mobilization of Hematopoietic Stem/Progenitor Cells.

Leah A. Marquez-Curtis - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

AMD-3100

GATA1s Induces Hyperproliferation of Eosinophil Precursors.

Katarina Reinhardt - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Down syndrome

N/A

Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML

Dawn Sheppard - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute myelocytic leukemia

N/A

Deep Phenotypic Characterization of Primitive Stem and Progenitor Compartments Reveals the Cellular Architecture of Aplastic Anemia.

Sasan Zandi - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

N/A

Fetal Vs. Adult Hematopoietic Progenitors Respond Differently to NOTCH1: Implications for Pediatric Vs. Adult T-ALL.

Sonya H Lam - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

T-cell acute lymphoblastic leukemia

N/A

Pneumococcal Bacteremia Among Patients with Hematological Malignancies: Clinical Impact, Serotype Distribution and Antibiotic Resistance Profile in Tertiary-Care Centers

Shi Hann Su - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

Pneumococcal polysaccharide vaccine

Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants

Denise Avard - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.

Todd A. Alonzo - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

miR155

Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.

Hae-Young Kim - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary arterial hypertension

Arginine hydrochloride

Epigenetic Therapy Inhibits NUP98-HOXA9-Mediated Myeloid Disease Decitabine and Valproic Acid Work Synergistically to Rescue Normal Hematopoiesis in Transgenic Zebrafish.

Adam P Deveau - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Decitabine

The Conserved Kxgffkr Motif of ?-Integrin Cytoplasmic Tail Mediates Chemoresistance to Doxorubicin in T-Cell Leukemia.

Pascal Leclair - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Doxorubicin

Different Characteristics Identified by Single Nucleotide Polymorphism Array Analsysis in Leukemia Suggest the Need for Different Application Strategics Depending On Disease Category.

Chul Won Jung - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic myelomonocytic leukemia

N/A

Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.

Anna M. Eiring - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Imatinib

Filters

28841 Abstracts